NCT07242131Recruiting
Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS
Comparison of the Efficacy of Oral Contraceptive, Progesterone, and Inositol Use in Regulating Menstrual Cycles in Patients With Polycystic Ovary Syndrome (PCOS)
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
This cross-sectional study aims to compare the effectiveness of oral contraceptives, oral progesterone (didrogesterone), and inositol in regulating menstrual cycles among women diagnosed with polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, hyperandrogenism, and polycystic ovarian morphology. While oral contraceptives are the mainstay of treatment, their use may be contraindicated in patients with cardiovascular risk factors, liver dysfunction, or in those who desire pregnancy. This study investigates whether oral progesterone and myo-inositol can serve as effective and safer alternatives for menstrual regulation and improvement of ovarian morphology and hyperandrogenic symptoms. A total of 150 women aged 15-40 years with a diagnosis of PCOS will be enrolled and divided into three equal groups: Group 1: Oral contraceptive users Group 2: Oral progesterone users Group 3: Inositol users The study will assess changes in menstrual regularity, ovarian morphology (via ultrasound), and clinical features such as hirsutism and acne before and after treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Ege University
- NCT number
- NCT07242131
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 1 Dec 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnancy or current use of hormonal therapy within the past 3 months.
Other illness
- Known hepatic, renal, cardiovascular, or endocrine disorders other than PCOS.
- History of thromboembolic disease, breast cancer, or other contraindications to hormonal treatment.
- Severe cognitive or communication impairment that prevents proper consent or data collection.
- Known allergy or hypersensitivity to any component of the study drugs.
Other
- Inability to adhere to follow-up visits or treatment regimen.
- Participation in another interventional study within the past 3 months.
Who the study is looking for
- Female participants aged 18 to 40 years.
- Diagnosed with polycystic ovary syndrome (PCOS) according to the ESHRE/ASRM (Rotterdam) criteria (presence of at least two of the following: oligo/anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology).
- No significant comorbid systemic disease.
- Willingness to participate and ability to provide written informed consent.
- Regular follow-up availability for at least 6 months.
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Izmir Bakircay University Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.